Explore
Validate
Learn
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [0]
- Comments [0]
- Validations
- Western blot [1]
- ELISA [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- RA0483 - Provider product page
- Provider
- Oursmab
- Product name
- Emibetuzumab (Biosimilar Reference Antibody) (MET)
- Antibody type
- Monoclonal
- Description
- Emibetuzumab (development code LY2875358) is an investigational, humanized bivalent monoclonal antibody developed for the treatment of solid tumors. It functions as a dual-action antagonist of the mesenchymal-epithelial transition factor (MET) receptor. Unlike simple competitive inhibitors, emibetuzumab is engineered to achieve two key effects: first, it blocks the binding of the natural MET ligand, hepatocyte growth factor (HGF), preventing receptor activation; and second, it induces the internalization and degradation of the MET receptor from the cancer cell surface. This two-pronged approach aims to achieve a more profound and sustained suppression of the oncogenic MET signaling pathway.
- Reactivity
- Human
- Isotype
- IgG
- Vial size
- 100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg
- Concentration
- Bottled at the concentration indicated on the vial.
- Storage
- Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.
No comments: Submit comment
Supportive validation
- Submitted by
- Oursmab (provider)
- Main image
- Experimental details
- Emibetuzumab (Biosimilar Reference Antibody) (MET)-RA0483-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.
Supportive validation
- Submitted by
- Oursmab (provider)
- Main image
- Experimental details
- ELISA plate pre-coated Antigen protein, can bind Emibetuzumab (Biosimilar Reference Antibody) (MET)-RA0483 in a linear range of 3.91-125 ng/mL.
